Napredna pretraga

Pregled bibliografske jedinice broj: 770684

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options


Milić, Sandra; Mikolašević, Ivana; Krznarić-Zrnić, Irena; Stanić, Marija; Poropat, Goran; Štimac, Davor; Vlahović-Palčevski, Vera; Orlić, Lidija
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options // Drug Design Development and Therapy, 9 (2015), 4835-4845 doi:10.2147/DDDT.S64877 (međunarodna recenzija, pregledni rad, znanstveni)


Naslov
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options

Autori
Milić, Sandra ; Mikolašević, Ivana ; Krznarić-Zrnić, Irena ; Stanić, Marija ; Poropat, Goran ; Štimac, Davor ; Vlahović-Palčevski, Vera ; Orlić, Lidija

Izvornik
Drug Design Development and Therapy (1177-8881) 9 (2015); 4835-4845

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
Nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; therapy

Sažetak
Diet and lifestyle changes have led to worldwide increases in the prevalences of obesity and metabolic syndrome, resulting in substantially greater incidence of nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic manifestation of metabolic syndrome and is related to diabetes, insulin resistance (IR), central obesity, hyperlipidemia, and hypertension. Nonalcoholic steatohepatitis (NASH) is an entity that describes liver inflammation due to NAFLD. Growing evidence suggests that NAFLD is a multisystem disease with a clinical burden that is not only confined to liver-related morbidity and mortality, but that also affects several extra-hepatic organs and regulatory pathways. Thus, NAFLD is considered an important public health issue, but there is currently no effective therapy for all NAFLD patients in the general population. Studies seeking optimal therapy for NAFLD and NASH have not yet led to development of a universal protocol for treating this growing problem. Several pharmacological agents have been studied in an effort to improve IR and the pro-inflammatory mediators that may be responsible for NASH progression. Cardiovascular risk factors are highly prevalent among NASH patients, and the backbone of treatment regimens for these patients still comprises general lifestyle interventions, including dietary changes and increased physical activity. Vitamin E and thiazolidinedione derivatives are currently the most evidence-based therapeutic options, but only limited clinical evidence is available regarding their long-term efficacy and safety. Vitamin D and renin–angiotensin–aldosterone system blockers are promising drugs that are currently being intensively investigated for use in NAFLD/NASH patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati